Pacific Biosciences of California, Inc. (PACB)

Market Cap	447.13M
Revenue (ttm)	152.36M
Net Income (ttm)	-657.75M
Shares Out	300.08M
EPS (ttm)	-2.34
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	13,280,349
Open	1.310
Previous Close	1.290
Day's Range	1.290 - 1.495
52-Week Range	0.851 - 2.720
Beta	2.16
Analysts	Buy
Price Target	2.06 (+38.26%)
Earnings Date	Aug 6, 2025

About PACB

Pacific Biosciences of California, Inc. designs, develops, and manufactures sequencing solution to resolve genetically complex problems. The company provides sequencing systems; consumable products, including single molecule real-time (SMRT) technology; long-read sequencing; and various reagent kits designed for specific workflow, such as preparation kit to convert DNA into SMRTbell double-stranded DNA library formats, including molecular biology reagents, such as ligase, buffers, and exonucleases. It also offers binding kits, such as modified ...

• Industry: Medical Devices
• Sector: Healthcare
• IPO Date: Oct 27, 2010
• Employees: 575
• Stock Exchange: NASDAQ
• Ticker Symbol: PACB
• Website: https://www.pacb.com

Financial Performance

In 2024, PACB's revenue was $154.01 million, a decrease of -23.19% compared to the previous year's $200.52 million. Losses were -$309.85 million, 1.02% more than in 2023.

Analyst Summary

According to 9 analysts, the average rating for PACB stock is "Buy." The 12-month stock price target is $2.06, which is an increase of 38.26% from the latest price.

Price Target

$2.06

(38.26% upside)

Analyst Consensus: Buy